Criticism of cancer treatment limitation

Regional health councils have been criticised by a team of prostate cancer specialists for preventing certain patients from receiving a new form of medication.

In approving treatment with the medication Xtandi, which costs 1,000 kroner per day to use, regional councils said it would not be made available to individuals who had already been treated with Zytiga, another form of medication.

Doctors said there was no medical argument for not treating prostate cancer with the new form of medication, leaving the only explanation for the decision to be financial considerations.

A spokesperson for regional councils said studies showed that giving both medications showed no benefit.

Jyllands-Posten

This story was included in The Copenhagen Post's Morning Briefing for Monday, September 10If you would like to receive stories like these delivered to your inbox by 8am each weekday, sign up for our Morning Briefing newsletter today. 





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.